默沙东在中国递交了皮下注射版PD-1抑制剂帕博利珠单抗的上市申请,该药物含透明质酸酶可促吸收,其关键性Ⅲ期研究显示,在转移性非小细胞肺癌一线治疗中,皮下注射版效果不劣于静脉注射。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.